At the news
? NEUTRALIMPACT 2/10 144 filed Jun 24, 2026 at 17:30 ET
Atlas Venture Fund X, L.P., a venture capital firm and early investor in Kymera Therapeutics, filed a Form 144 notice of intent to sell 118,178 shares of common stock, valued at approximately $11.6 million. This follows a series of large sales by Atlas entities in June 2026, totaling hundreds of thousands of shares, consistent with a venture fund distributing to limited partners. The proposed sale represents a small fraction (0.12%) of Kymera's $9.4B market cap and is not a signal of fundamental deterioration.
- Atlas Venture Fund X, L.P. filed a Form 144 to sell 118,178 shares of Kymera Therapeutics common stock.
- Estimated market value of the proposed sale is $11,610,988.50.
- Shares were acquired in a private placement on March 11, 2020.
- Atlas entities have sold over 450,000 shares in June 2026 alone, including 243,976 shares on June 22, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access